《生命科学》 2022, 34(6): 663-675

CD19 CAR-T细胞治疗急性B淋巴细胞白血病的研究进展

姚　桦^1,2 , 杨晓梅^2,3 , 钟大妮^2,* , 卢小玲^1,2,*

¹广西医科大学口腔医学院，口腔应用基础教研室，南宁 530021 ²广西医科大学基础医学院， 广西纳米抗体国际联合研究中心，南宁 530021 ³广西医科大学基础医学院，生理学教研室，南宁 530021

摘　要：

嵌合抗原受体T 细胞(chimeric antigen receptor T cell, CAR-T) 是一种新型免疫治疗方法。多项临床研究结果显示，靶向CD19 的CAR-T 细胞治疗复发难治性急性B 淋巴细胞白血病(B-cell acute lymphoblastic leukemia, B-ALL) 效果显著，为复发难治性B-ALL 患者带来福音。CAR-T 细胞治疗被认为是最有潜力的免疫治疗手段。该文综述了近年来CD19 CAR-T 细胞治疗B-ALL 的临床研究进展及改进策略。

通讯作者：钟大妮 , Email:danizhong_gxmu@163.com 卢小玲 , Email:luxiaoling@gxmu.edu.cn

Research progress on CD19 CAR-T therapy in treating B-cell acute lymphocytic leukemia

YAO Hua^1,2 , YANG Xiao-Mei^2,3 , ZHONG Da-Ni^2,* , LU Xiao-Ling^1,2,*

¹Department of Stomatology, Stomatology College of Guangxi Medical University, Nanning 530021, China ²International Nanobody Research Center of Guangxi, Basic Medical College of Guangxi Medical University, Nanning 530021, China ³Department of Physiology, Basic Medical College of Guangxi Medical University, Nanning 530021, China

Abstract:

Chimeric antigen receptor T cell (CAR-T) is a new type of immunotherapy. The results of a number of clinical studies have shown that CAR-T cells targeting CD19 have a significant effect on the treatment of B-cell acute lymphoblastic leukemia (B-ALL), bringing good news to patients with relapsed and refractory B-ALL. CAR-T cell therapy is considered to be the most potential immunotherapy. This article describes the progress in clinical research and improvement strategies of CD19 CAR-T cell therapy for B-ALL in recent years.

Communication Author：ZHONG Da-Ni , Email:danizhong_gxmu@163.com LU Xiao-Ling , Email:luxiaoling@gxmu.edu.cn